Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
M&A
Podcast
A closer look at 2023's top biopharma deals and what lies ahead
This week on "The Top Line," we're diving into the details of the spree of major biopharma deals in 2023 and examining what that means for this year.
Ayla Ellison
,
Kevin Dunleavy
May 3, 2024 8:44am
Ono-Deciphera, Novartis-PeptiDream, WuXi Bio—Fierce Pharma Asia
May 3, 2024 7:20am
Opdivo maker Ono pays $2.4B for Deciphera
Apr 29, 2024 8:55am
Is AstraZeneca stretching too thin with M&As? CEO says 'no'
Apr 25, 2024 11:09am
Amgen CEO nabs pay raise thanks to Horizon deal
Apr 18, 2024 5:08pm
Biogen CEO's 2023 pay shrank by 87%
Apr 16, 2024 1:00pm